×
Sunday, November 15, 2026

CVRx Securities Class Action (CVRX) — Investor Lawsuit - openclassactions.com

Investors who bought CVRx common stock between July 25, 2023 and August 6, 2026 may be covered by a proposed securities class action alleging CVRx and four current and former executives hid that Barostim sales growth depended in part on improper marketing and payment practices, the subject of a Justice Department investigation the company disclosed in August 2026. No class has been certified and there is nothing to file yet.

This article describes a class action complaint. The statements below are unproven allegations. CVRx has not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.

What Is This About?

A pension fund filed a proposed securities class action against CVRx, Inc. (NASDAQ: CVRX), the Minneapolis-area maker of the Barostim implant for heart failure, on November 9, 2026. The case is Oklahoma Police Pension and Retirement System v. CVRx, Inc., No. 0:26-cv-04746, in the U.S. District Court for the District of Minnesota, before Judge Eric C. Tostrud. It is brought on behalf of everyone who bought CVRx common stock from July 25, 2023 through August 6, 2026.

The complaint names CVRx; Kevin Hykes, president and CEO since February 2024; Nadim Yared, CEO from 2006 to February 2024; Jared Oasheim, the chief financial officer through 2026; and Robert John, chief revenue officer from June 2024 to August 2026. It asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of...



Read Full Story: https://news.google.com/rss/articles/CBMiekFVX3lxTE5VMVhZbWtxYmdtQmNmWFZDb2ds...